Nomenclature for human DPYD alleles

H L  McLeod; E S R  Collie-Duguid; P  Vreken; M R  Johnson; X  Wei; A  Sapone; R B  Diasio; P  Fernandez-Salguero; A B P  van Kuilenberg; A H  van Gennip; F J  Gonzalez

Nomenclature for human DPYD alleles

H L McLeod, E S R Collie-Duguid, P Vreken, M R Johnson, X Wei, A Sapone, R B Diasio, P Fernandez-Salguero, A B P van Kuilenberg, A H van Gennip, F J Gonzalez

Applied Medicine

Research output: Contribution to journal › Article

94 Citations (Scopus)

Abstract

To standardize DPYD allele nomenclature and to conform with international human gene nomenclature guidelines, an alternative to the current arbitrary system is described. Based on recommendations for human genome nomenclature, we propose that each distinct allele be designed by DPYD followed by an asterisk and an Arabic numeral. The number specifies the key mutation and, where appropriate, a letter following the number indicates an additional mutation on the mutant allele, Criteria for classification as a distinct allele are also presented. Pharmacogenetics 8:455-459. (C) 1998 Lippincott Williams & Wilkins.

Original language	English
Pages (from-to)	455-459
Number of pages	5
Journal	Pharmacogenetics
Volume	8
Publication status	Published - 1998

Keywords

allele nomenclature
DPYD
dihydropyrimidine dehydrogenase
pyrimidine metabolism
DIHYDROPYRIMIDINE DEHYDROGENASE-DEFICIENCY
5-FLUOROURACIL TOXICITY
MONONUCLEAR-CELLS
CANCER-PATIENTS
MOLECULAR-BASIS
GENE
IDENTIFICATION
CHEMOTHERAPY
POPULATION
LIVER

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Cite this

@article{429b8a1dd1164d42bc0ce32deac6f5a3,

title = "Nomenclature for human DPYD alleles",

abstract = "To standardize DPYD allele nomenclature and to conform with international human gene nomenclature guidelines, an alternative to the current arbitrary system is described. Based on recommendations for human genome nomenclature, we propose that each distinct allele be designed by DPYD followed by an asterisk and an Arabic numeral. The number specifies the key mutation and, where appropriate, a letter following the number indicates an additional mutation on the mutant allele, Criteria for classification as a distinct allele are also presented. Pharmacogenetics 8:455-459. (C) 1998 Lippincott Williams & Wilkins.",

keywords = "allele nomenclature, DPYD, dihydropyrimidine dehydrogenase, pyrimidine metabolism, DIHYDROPYRIMIDINE DEHYDROGENASE-DEFICIENCY, 5-FLUOROURACIL TOXICITY, MONONUCLEAR-CELLS, CANCER-PATIENTS, MOLECULAR-BASIS, GENE, IDENTIFICATION, CHEMOTHERAPY, POPULATION, LIVER",

author = "McLeod, {H L} and Collie-Duguid, {E S R} and P Vreken and Johnson, {M R} and X Wei and A Sapone and Diasio, {R B} and P Fernandez-Salguero and {van Kuilenberg}, {A B P} and {van Gennip}, {A H} and Gonzalez, {F J}",

year = "1998",

language = "English",

volume = "8",

pages = "455--459",

journal = "Pharmacogenetics",

issn = "0960-314X",

publisher = "Lippincott Williams and Wilkins",

}

TY - JOUR

T1 - Nomenclature for human DPYD alleles

AU - McLeod, H L

AU - Collie-Duguid, E S R

AU - Vreken, P

AU - Johnson, M R

AU - Wei, X

AU - Sapone, A

AU - Diasio, R B

AU - Fernandez-Salguero, P

AU - van Kuilenberg, A B P

AU - van Gennip, A H

AU - Gonzalez, F J

PY - 1998

Y1 - 1998

N2 - To standardize DPYD allele nomenclature and to conform with international human gene nomenclature guidelines, an alternative to the current arbitrary system is described. Based on recommendations for human genome nomenclature, we propose that each distinct allele be designed by DPYD followed by an asterisk and an Arabic numeral. The number specifies the key mutation and, where appropriate, a letter following the number indicates an additional mutation on the mutant allele, Criteria for classification as a distinct allele are also presented. Pharmacogenetics 8:455-459. (C) 1998 Lippincott Williams & Wilkins.

AB - To standardize DPYD allele nomenclature and to conform with international human gene nomenclature guidelines, an alternative to the current arbitrary system is described. Based on recommendations for human genome nomenclature, we propose that each distinct allele be designed by DPYD followed by an asterisk and an Arabic numeral. The number specifies the key mutation and, where appropriate, a letter following the number indicates an additional mutation on the mutant allele, Criteria for classification as a distinct allele are also presented. Pharmacogenetics 8:455-459. (C) 1998 Lippincott Williams & Wilkins.

KW - allele nomenclature

KW - DPYD

KW - dihydropyrimidine dehydrogenase

KW - pyrimidine metabolism

KW - DIHYDROPYRIMIDINE DEHYDROGENASE-DEFICIENCY

KW - 5-FLUOROURACIL TOXICITY

KW - MONONUCLEAR-CELLS

KW - CANCER-PATIENTS

KW - MOLECULAR-BASIS

KW - GENE

KW - IDENTIFICATION

KW - CHEMOTHERAPY

KW - POPULATION

KW - LIVER

M3 - Article

VL - 8

SP - 455

EP - 459

JO - Pharmacogenetics

JF - Pharmacogenetics

SN - 0960-314X

ER -

Nomenclature for human DPYD alleles

Abstract

Keywords

UN SDGs

Fingerprint

Cite this